Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

Rhea-AI Summary

DBVT (DBVT) reports the total number of shares and voting rights as of February 28, 2026 under Article 223-16 of the AMF General Regulations. The company lists 278,352,082 total shares and a total gross voting rights count of 278,352,082.

The total net voting rights (excluding shares without voting rights) is 278,236,200. Market: NYSE Euronext Paris. ISIN: FR0010417345.

Key Figures

Total shares: 278,352,082 Total gross voting rights: 278,352,082 Total net voting rights: 278,236,200

3 metrics

Total shares 278,352,082 As of February 28, 2026

Total gross voting rights 278,352,082 As of February 28, 2026

Total net voting rights 278,236,200 As of February 28, 2026 (excludes shares without voting rights)

Market Reality Check

Price: $23.25 Vol: Volume 179,284 is below 2...

low vol

$23.25 Last Close

Volume Volume 179,284 is below 20-day average 263,471 (relative volume 0.68x). low

Technical Trading above 200-day MA: price 21.87 vs 200-day MA 13.78, near the 52-week range high (-16.48% below high, well above low).

Peers on Argus

DBVT gained 10.77% while only one momentum-flagged peer (NGNE) moved in the oppo...

1 Down

DBVT gained 10.77% while only one momentum-flagged peer (NGNE) moved in the opposite direction (-2.96%), indicating today’s move appears stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Feb 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Clinical data update	Positive	-5.0%	Additional positive Phase 3 VITESSE data and EPIT discussion at AAAAI 2026.
Feb 09	Conference participation	Positive	+7.1%	CEO fireside chat at Guggenheim biotech summit with webcast access.
Feb 05	Voting rights update	Neutral	-0.9%	Disclosure of total shares and gross/net voting rights as of Jan 31, 2026.
Jan 16	Financing proceeds	Positive	+0.5%	€166.7M gross proceeds from full exercise of ABSA and BS warrants.
Jan 12	Voting rights restatement	Neutral	-5.0%	Updated share and voting-right totals as of Dec 31, 2025, superseding prior data.

Pattern Detected

Recent news shows mixed reactions: clinical and capital-raising milestones sometimes saw negative or muted moves, while conference participation and some financing news aligned with modest gains. Routine voting-rights disclosures have coincided with small to negative moves.

Recent Company History

Over the past few months, DBV Technologies has reported several capital structure and clinical milestones. Governance updates on total shares and voting rights as of December 31, 2025, January 31, 2026, and now February 2026 highlight ongoing share issuance and warrant exercises. A March 2025 financing later yielded €166.7 million in gross proceeds, supporting operations and regulatory preparation. Meanwhile, positive VITESSE Phase 3 data and upcoming presentations underscore the company’s focus on the VIASKIN Peanut Patch program. Today’s announcement continues the pattern of transparent reporting on share and voting-right dynamics.

Market Pulse Summary

This announcement details DBVT’s capital structure, confirming 278,352,082 shares and net voting rig...

Analysis

This announcement details DBVT’s capital structure, confirming 278,352,082 shares and net voting rights of 278,236,200 as of February 28, 2026. It follows recent disclosures showing rising share and warrant activity and prior monthly voting-rights updates. Investors tracking dilution and ownership dynamics can compare these figures to earlier month-end counts and to major-holder filings, while also watching how upcoming clinical and regulatory milestones interact with an expanded equity base over time.

Key Terms

isin code

1 terms

isin code financial

"Market : NYSE Euronext Paris ISIN Code: FR 0010417345"

An ISIN code is a unique identifier for a specific financial asset, like a stock or bond, similar to a product's barcode. It helps investors, traders, and banks quickly and accurately find and track that asset across different markets worldwide. This makes buying, selling, and managing investments more organized and reliable.

AI-generated analysis. Not financial advice.

Information Regarding the Total Number of Voting Rights and 
Total Number of Shares of the Company as of February 28, 2026

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris
ISIN Code: FR 0010417345

Date	Total number of shares	Total number of voting rights
02/28/2026	278,352,082	Total gross of voting rights: 278,352,082
		Total net* of voting rights: 278,236,200

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment

• PDF Version

FAQ

How many total shares did DBVT report as of February 28, 2026?

DBVT reported 278,352,082 total shares as of February 28, 2026. According to the company, this figure is the registered share count used for statutory disclosures under AMF rules.

What is the difference between DBVT's gross and net voting rights on February 28, 2026?

The gross voting rights were 278,352,082 and the net voting rights were 278,236,200 on that date. According to the company, net voting rights exclude shares without voting rights.

Which market and ISIN correspond to DBVT's February 28, 2026 disclosure?

The disclosure covers DBVT listed on NYSE Euronext Paris with ISIN FR0010417345. According to the company, the notice complies with AMF Article 223-16 reporting requirements.

Why did DBVT publish total voting rights information on March 3, 2026?

DBVT published the voting rights update to comply with AMF reporting rules and inform investors of shareholder metrics. According to the company, the data reflects the position as of February 28, 2026.

How should investors use DBVT's reported net voting rights figure for shareholder votes?

Investors should use the net voting rights of 278,236,200 to estimate voting power at shareholder meetings. According to the company, net rights exclude shares that carry no voting entitlement.